Iobenguane I 131 is under clinical development by Lantheus and currently in Phase II for Neuroblastoma. According to GlobalData, Phase II drugs for Neuroblastoma have a 28% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Iobenguane I 131’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Iobenguane I 131 overview

Iobenguane I 131 (Azedra) is a therapeutic radio-pharmaceutical agent. It is formulated as injectable solution for intravenous route of administration. Azedra is indicated for the treatment of adult and pediatric patients 12 years and older with iobenguane scan positive, unresectable, locally advanced or metastatic pheochromocytoma or paraganglioma who require systemic anticancer therapy.

Ultratrace Iobenguane I 131 is under development for the treatment of neuroblastoma. The drug candidate is administered as an intravenous injection. It is a small molecule, targeted radiotherapeutic based on the known I-131 MIBG molecule developed based on Ultratrace technology which is a technique that avoids large quantities of non-radioactive iobenguane in the formulation of the product. It was under development for the treatment of neuroblastoma (EU).

Lantheus overview

Lantheus is engaged in the development, manufacture, sale and distribution of diagnostic medical imaging agents and products that assist clinicians in the diagnosis of cardiovascular and other diseases. The company offers products including DEFINITY, VIALMIX, PINSYNC, TechneLite, Xenon-133, Calidose Dispenser System, NEUROLITE, Thallium-201, QUADRAMET, Cardiolite, Gallium-67, Fludeoxyglucose F 18 Injection and ABLAVAR. Lantheus sells its products to radiopharmacies, hospitals, clinics, group practices, integrated delivery networks, group purchasing organizations, and wholesalers. The company has operations in the US, Puerto Rico, Canada and Australia and distribution relationships in Europe, Asia Pacific and Latin America. Lantheus is headquartered in North Billerica, Massachusetts, the US.

For a complete picture of Iobenguane I 131’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.